Development and validation of high performance liquid chromatographic method for estimation of brimonidine tartrate as bulk drug and in ophthalmic formulation was written by Rohan, Barse;Amol, Tagalpallewar;Chandrakant, Kokare;Shrivastava, Birendra. And the article was included in International Journal of PharmTech Research in 2019.COA of Formula: C15H16BrN5O6 This article mentions the following:
Glaucoma is complex disease characterized by ocular hypertension with a progressive visual loss that could resist in blindness due to damage occurred to optic nerve. Brimonidine tartrate is commonly used drug in glaucoma therapy which is selective alpha 2 adrenergic agonist. The reverse phase high performance liquid chromatog. method was developed and validated for estimation of brimonidine tartrate in bulk drug and pharmaceutical dosage form. Better separation was achieved on Kromasil C 18 ( 250 mm X 4.6 mm i.d., 5μm particle size) column using isocratic elution program with mobile phase citric acid monohydrate buffer : water: methanol (30:50:20 volume/volume/v) and pH 3 was maintained by using triethylamine. The flow rate was 1.0 mL/min. Elute was detected at 246 nm and it effectively separated at retention time of 6 min. The developed method was successfully validated according to ICH guidelines. The method was validated for linearity, accuracy, specificity, precision and robustness. The LOD and LOQ was 1.47 and 4.47μg/mL resp. The optimized and validated method can be used for estimation of brimonidine tartrate in bulk and in ophthalmic formulation. In the experiment, the researchers used many compounds, for example, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5COA of Formula: C15H16BrN5O6).
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5) belongs to quinoxaline derivatives. Condensed heterocycles of quinoxalines have become attractive targets in synthetic and medicinal chemistry due to their significant biological activities. Quinoxaline and its analogues may also be formed by reduction of amino acids substituted 1,5-difluoro-2,4-dinitrobenzene (DFDNB),One study used 2-iodoxybenzoic acid (IBX) as a catalyst in the reaction of benzil with 1,2-diaminobenzene.COA of Formula: C15H16BrN5O6
Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider